Skip to main content

Prostate disorders : procurement of biomarkers and pharmaceuticals

Objective

we will procure biomarkers and pharmaceuticals for prostate disorders. About 1 in 4 men over 55 have lower urinary tract symptoms due to benign prostatic hyperplasia, and 1 in 10 a lifetime risk of prostate cancer. Prostate disorders are a growing major socio-economic challenge because of our ageing population. We are clinicians, scientists and industrialists with complementary expertise and proven ability to collaborate. We will use prostate samples that are clinically well-defined and proprietary (DATAS) and established (suppression subtractive hybridisation, proteomics) approaches to identify changes in gene expression. We will show in clinical and model systems that these changes are important for prostate pathogenesis, and develop diagnostic/prognostics biomarkers and therapeutics for the painful and debilitating disorders of the prostate.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Address
Rue René Descartes 15
67084 Strasbourg
France

Participants (6)

EXONHIT THERAPEUTICS S.A.
France
Address
Boulevard Masséna, 65
75013 Paris
FORSCHUNGSZENTRUM KARLSRUHE GMBH - TECHNIK UND UMWELT
Germany
Address
Hermann Von Helmholtz Platz 1
76021 Karlsruhe
LEOPOLD-FRANZENS-UNIVERSITAET INNSBRUCK
Austria
Address
Anichstrasse 35
6020 Innsbruck
PROTEOSYS AG
Germany
Address
Kupferberterrasse 17-19
55116 Mainz
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
Address
Geert Grooteplein 10
6500 HB Nijmegen
WEIZMANN INSTITUTE OF SCIENCE
Israel
Address
Herzl Street 26
76100 Rehovot